174 related articles for article (PubMed ID: 28392480)
1. Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.
McGee SR; Tibiche C; Trifiro M; Wang E
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):121-129. PubMed ID: 28392480
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
3. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutation associates with improved outcome in breast cancer.
Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W; Moynahan ME
Clin Cancer Res; 2009 Aug; 15(16):5049-59. PubMed ID: 19671852
[TBL] [Abstract][Full Text] [Related]
5. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
6. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
[TBL] [Abstract][Full Text] [Related]
7. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
8. Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer.
Anabel Sinberger L; Zahavi T; Sonnenblick A; Salmon-Divon M
Sci Rep; 2023 Nov; 13(1):20911. PubMed ID: 38017109
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
[TBL] [Abstract][Full Text] [Related]
10.
Tang Y; Li J; Xie N; Yang X; Liu L; Wu H; Tian C; He Y; Wang X; He Q; Hu ZY; Ouyang Q
Aging (Albany NY); 2020 Jan; 12(2):1577-1590. PubMed ID: 31980592
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
Pérez-Tenorio G; Alkhori L; Olsson B; Waltersson MA; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
Clin Cancer Res; 2007 Jun; 13(12):3577-84. PubMed ID: 17575221
[TBL] [Abstract][Full Text] [Related]
12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Moon WK; Chen HH; Shin SU; Han W; Chang RF
Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
[TBL] [Abstract][Full Text] [Related]
14. The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL; Spies NC; Anurag M; Griffith M; Luo J; Tu D; Yeo B; Kunisaki J; Miller CA; Krysiak K; Hundal J; Ainscough BJ; Skidmore ZL; Campbell K; Kumar R; Fronick C; Cook L; Snider JE; Davies S; Kavuri SM; Chang EC; Magrini V; Larson DE; Fulton RS; Liu S; Leung S; Voduc D; Bose R; Dowsett M; Wilson RK; Nielsen TO; Mardis ER; Ellis MJ
Nat Commun; 2018 Sep; 9(1):3476. PubMed ID: 30181556
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Characteristics of
Lee MH; Cho JH; Kwon SY; Jung SJ; Lee JH
Int J Med Sci; 2020; 17(8):1131-1135. PubMed ID: 32410843
[TBL] [Abstract][Full Text] [Related]
16. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
17. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
[TBL] [Abstract][Full Text] [Related]
18. Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
Mishima C; Kagara N; Ikeda JI; Morii E; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Am J Pathol; 2018 May; 188(5):1106-1112. PubMed ID: 29454754
[TBL] [Abstract][Full Text] [Related]
19. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
20. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]